Insider Transactions in Q4 2021 at Cognition Therapeutics Inc (CGTX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 13
2021
|
Peggy Wallace Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$36,000
$12.0 P/Share
|
|
Oct 13
2021
|
Mark H. Breedlove Director |
SELL
Open market or private sale
|
Indirect |
11
-0.0%
|
$132
$12.0 P/Share
|
|
Oct 13
2021
|
Mark H. Breedlove Director |
BUY
Conversion of derivative security
|
Indirect |
404,451
+28.67%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Ogden Cap Associates, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
74
-0.0%
|
$888
$12.0 P/Share
|
|
Oct 13
2021
|
Ogden Cap Associates, LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
27,471
+1.23%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Ogden Cap Associates, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,182,981
+27.32%
|
-
|
|
Oct 13
2021
|
Golden Seeds Cognition Therapeutics LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,477,449
+29.89%
|
-
|
|
Oct 13
2021
|
Golden Seeds Cognition Therapeutics LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
33
-0.0%
|
$396
$12.0 P/Share
|
|
Oct 13
2021
|
Golden Seeds Cognition Therapeutics LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
12,276
+0.56%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Aaron G.L. Fletcher Director |
BUY
Conversion of derivative security
|
Indirect |
3,689,437
+44.16%
|
-
|
|
Oct 13
2021
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
190,000
+20.92%
|
$2,280,000
$12.0 P/Share
|
|
Oct 13
2021
|
Aaron G.L. Fletcher Director |
SELL
Open market or private sale
|
Indirect |
90
-0.02%
|
$1,080
$12.0 P/Share
|
|
Oct 13
2021
|
Aaron G.L. Fletcher Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
33,495
+8.0%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Bios Memory Spv I, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,265,423
+43.68%
|
-
|
|
Oct 13
2021
|
Bios Memory Spv I, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
190,000
+20.92%
|
$2,280,000
$12.0 P/Share
|
|
Oct 13
2021
|
Bios Memory Spv I, LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
90
-0.02%
|
$1,080
$12.0 P/Share
|
|
Oct 13
2021
|
Bios Memory Spv I, LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
33,495
+8.0%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Bios Memory Spv I, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,424,014
+50.0%
|
-
|
|
Oct 13
2021
|
James Michael O'Brien Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$60,000
$12.0 P/Share
|
|
Oct 13
2021
|
Lisa Ricciardi CEO & President |
BUY
Open market or private purchase
|
Direct |
12,500
+50.0%
|
$150,000
$12.0 P/Share
|